Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Clinical evidence

ABX464-FE-001

24 evidence topics · 2 sources

Objective
Location and study date
Study dates and status in the registry record
FieldRegistry entry
Recruitment status“Completed”
Study start“2014-09”
Primary completion (actual)“2015-06”
Other study ID numbers“ABX464-FE-001”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using single-dose AUC and cmax under fed and fasted conditions as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Study limitations
Summary

ABX464-FE-001 enrolled 48 healthy men in Mauritius in 2014 and 2015, 24 per group; the registry described 40 healthy Caucasian men. The repeated-dose group received 50 mg every 3 days, a schedule the authors chose for safety reasons, and compared fed and fasted conditions in a parallel design. The authors state that the study “does have a number of intrinsic limitations”: women were excluded, no age effects could be analyzed, and the terminal elimination rate constant after a single dose could be determined in only 17 participants fasted and 13 fed. One participant without quantifiable fasted concentrations was excluded from the pharmacokinetic analysis, and four authors are Abivax employees.